Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma

Abstract Background Olaratumab, a fully human monoclonal antibody, selectively binds to human platelet‐derived growth factor receptor alpha and blocks ligand binding. This study assessed the effect of olaratumab on the pharmacokinetics (PK) of doxorubicin and the safety of olaratumab alone and in co...

Full description

Bibliographic Details
Main Authors: Victor M. Villalobos, Gary Mo, Mark Agulnik, Seth M. Pollack, Daniel A. Rushing, Arun Singh, Brian A. Van Tine, Rhian McNaughton, Rodney L. Decker, Wei Zhang, Ashwin Shahir, Damien M. Cronier
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:Cancer Medicine
Subjects:
doxorubicin
monoclonal antibody
olaratumab
pharmacokinetics
soft tissue sarcoma
Online Access:https://doi.org/10.1002/cam4.2728

Internet

https://doi.org/10.1002/cam4.2728

Similar Items